LOXAPAC

This brand name is authorized in Canada, France.

Active ingredients

The drug LOXAPAC contains one active pharmaceutical ingredient (API):

1	Loxapine UNII LER583670J - LOXAPINE
	Loxapine binds with noradrenergic, histaminergic, and cholinergic receptors, and its interaction with these systems may influence the spectrum of its pharmacological effects. Loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.
	Read more about Loxapine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LOXAPAC IM Solution for injection	MPI, CA: SPM	Health Products and Food Branch (CA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05AH01	Loxapine	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AH Diazepines, oxazepines and thiazepines
Discover more medicines within N05AH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02169991
FR	Base de données publique des médicaments	64162292, 66002781, 69485940, 69700033, 69893582